Acasti Pharma EPS - Earnings per Share 2014-2024 | GRCE
Acasti Pharma eps - earnings per share from 2014 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Acasti Pharma Annual EPS |
| 2024 |
$-1.35 |
| 2023 |
$-5.71 |
| 2022 |
$-1.62 |
| 2021 |
$-7.98 |
| 2020 |
$-14.40 |
| 2019 |
$-35.03 |
| 2018 |
$-46.05 |
| 2017 |
$-35.50 |
| 2016 |
$-21.74 |
| 2015 |
$-9.60 |
| 2015 |
$0.00 |
| 2014 |
$-67.19 |
| 2014 |
$0.00 |
| 2013 |
$-43.19 |
| 2013 |
$0.00 |
| Acasti Pharma Quarterly EPS |
| 2024-06-30 |
$-0.24 |
| 2024-03-31 |
$-0.17 |
| 2023-12-31 |
$-0.21 |
| 2023-09-30 |
$-0.43 |
| 2023-06-30 |
$-0.54 |
| 2023-03-31 |
$-3.92 |
| 2022-12-31 |
$-0.52 |
| 2022-09-30 |
$-0.66 |
| 2022-06-30 |
$-0.61 |
| 2022-03-31 |
$-0.54 |
| 2021-12-31 |
$-0.54 |
| 2021-09-30 |
$0.18 |
| 2021-06-30 |
$-0.72 |
| 2021-03-31 |
$-0.90 |
| 2020-12-31 |
$-1.56 |
| 2020-09-30 |
$-3.12 |
| 2020-06-30 |
$-2.40 |
| 2020-03-31 |
$9.60 |
| 2019-12-31 |
$-6.72 |
| 2019-09-30 |
$-12.00 |
| 2019-06-30 |
$-5.28 |
| 2019-03-31 |
$-1.17 |
| 2018-12-31 |
$-2.54 |
| 2018-09-30 |
$-22.77 |
| 2018-06-30 |
$-8.56 |
| 2018-03-31 |
$-12.59 |
| 2017-12-31 |
$-14.81 |
| 2017-09-30 |
$-11.87 |
| 2017-06-30 |
$-6.78 |
| 2017-02-28 |
$-8.70 |
| 2016-11-30 |
$-7.96 |
| 2016-08-31 |
$-8.14 |
| 2016-05-31 |
$-10.71 |
| 2016-03-31 |
$-6.24 |
| 2016-02-29 |
$0.00 |
| 2015-12-31 |
$-7.68 |
| 2015-09-30 |
$-0.48 |
| 2015-06-30 |
$-4.80 |
| 2015-03-31 |
$-9.60 |
| 2014-12-31 |
$14.40 |
| 2014-09-30 |
$-14.40 |
| 2014-06-30 |
$4.80 |
| 2014-03-31 |
$-9.60 |
| 2014-02-28 |
$0.00 |
| 2013-12-31 |
$-24.00 |
| 2013-09-30 |
$-19.20 |
| 2013-06-30 |
$-14.40 |
| 2013-03-31 |
$-14.40 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
